Daniel Ninivaggi Purchases 775 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) Director Daniel Ninivaggi acquired 775 shares of the business’s stock in a transaction on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Indivior Price Performance

Indivior stock traded down $0.35 during trading on Wednesday, reaching $35.85. 1,097,072 shares of the company were exchanged, compared to its average volume of 1,460,802. The stock’s 50 day simple moving average is $33.69 and its two-hundred day simple moving average is $25.59. The company has a market capitalization of $4.48 billion, a P/E ratio of 38.96 and a beta of 0.75. Indivior PLC has a 52-week low of $7.62 and a 52-week high of $38.00.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The business had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. As a group, equities analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares in the last quarter. Goldentree Asset Management LP purchased a new position in Indivior in the third quarter valued at approximately $42,630,000. CIBC Bancorp USA Inc. acquired a new stake in Indivior during the third quarter worth approximately $312,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Indivior during the 3rd quarter worth approximately $33,496,000. Finally, Woodline Partners LP purchased a new stake in shares of Indivior during the 3rd quarter worth approximately $6,413,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on INDV shares. Northland Securities set a $40.00 target price on Indivior in a research note on Friday, October 31st. Craig Hallum reiterated a “buy” rating and set a $41.00 price target on shares of Indivior in a report on Friday, October 31st. HC Wainwright boosted their price target on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Morgan Stanley reissued an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $32.71.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.